Contrast-enhanced spectral mammography (CESM) was found superior to mammography and breast ultrasound, and comparable to breast MRI, in detecting ductal carcinoma in situ (DCIS), found a study published in Clinical Breast Cancer.

“Visibility on mammography, breast US, CESM, and breast MRI were 44%, 76%, 58%, and 80% for pure DCIS, and 73%, 81%, 86%, and 92% for underestimated DCIS,” wrote the team, led by Dr. Hee Jung Shin from the University of Ulsan in South Korea. Italics were added to highlight CESM results within the two groups.

The team further characterized the clinical implications of the technique, according to Allegretto. “‘CESM is a promising modality that shows the potential to assess both morphologies, including microcalcifications and perfusion characteristics, at lower cost and faster acquisition,’ Shin and colleagues wrote.”

Sources:

Hee Jung Shin, Woo Jung Choi, Seo Young Park, Sei Hyun Ahn, Byung Ho Son, Il Yong Chung, Jong Won Lee, Beom Seok Ko, Ji Sun Kim, Eun Young Chae, Joo Hee Cha, Hak Hee Kim. Prediction of Underestimation Using Contrast-Enhanced Spectral Mammography in Patients Diagnosed as Ductal Carcinoma In Situ on Preoperative Core Biopsy. Clinical Breast Cancer. Available online 9 October 2021, at https://www.clinical-breast-cancer.com/article/S1526-8209(21)00295-0/fulltext. Accessed October 31, 2021.

Allegretto, Amerigo. Contrast-enhanced mammography can predict underestimated DCIS. AuntMinnie.com October 14, 2021, at https://www.auntminnie.com/index.aspx?sec=sup&sub=wom&pag=dis&ItemID=133760. Accessed October 31, 2021.

Losurdo L, Fanizzi A, Basile TMA, Bellotti R, Bottigli U, Dentamaro R, Didonna V, Lorusso V, Massafra R, Tamborra P, Tagliafico A, Tangaro S, La Forgia D. Radiomics Analysis on Contrast-Enhanced Spectral Mammography Images for Breast Cancer Diagnosis: A Pilot Study. Entropy. 2019; 21(11):1110. https://doi.org/10.3390/e21111110. Accessed October 31, 2021.